CTT Pharmaceutical (CTTH) CEO & Director Buys 3,400 Shares

What Happened CTT Pharmaceutical Holdings' CEO and director reported a purchase of 3,400 shares (transaction code P) at $0.06 per share, for a total cash outlay of $187. The filing lists the trade as an open market or private purchase. Purchases by insiders can be interpreted as a bullish signal, though the dollar amount here is very small.

Key Details

• Transaction date per the report: 2026-09-24; Form 4 filed: 2026-09-28.
• Price and amount: 3,400 shares @ $0.06 each; total ≈ $187.
• Transaction type: P = Purchase (open market or private purchase as indicated).
• Shares owned after transaction: not reported in the provided filing.
• Filing timeliness: The Form 4 was filed four days after the transaction date (Sep 24 → Sep 28), which appears later than the standard 2-business-day SEC filing window.

Context

• This is a straightforward share purchase by an executive; the amount is very small relative to typical insider transactions, so it may be routine or personal in nature rather than a strong signal of company prospects.
• No options exercise, gifts, tax-withholding, or 10% owner issues were reported in the provided details.